lifestyle.tweeternet.com

Author: CorMedix, Inc.

CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

May 5, 2026
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

April 27, 2026
CorMedix to Participate in Needham Virtual Healthcare Conference

April 7, 2026
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 5, 2026
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

March 2, 2026
CorMedix to Participate in Upcoming Investor Conferences

February 12, 2026
CorMedix Therapeutics Announces Share Repurchase Program

February 9, 2026
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

January 29, 2026